ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE AND -EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Brian G. Feagan  ¹     Laurent Peyrin-Biroulet  ²     William Sandborn  ³     Geert R. D'Haens  ⁴     Julian Panés  ⁵     Andres Yarur  ⁶     Douglas C. Wolf  ⁷     Timothy Ritter  ⁸     Stefan Schreiber  ⁹     Sheldon Sloan  ¹⁰     Fabio Cataldi     Kevin Shan     Christopher J. Rabbat     Michael Chiorean  ¹¹     Filip Baert  ¹²     Bruce E. Sands  ¹³     Marla C. Dubinsky  ¹⁴     Severine Vermeire  ¹⁵     Martina Goetsch  ¹⁶     Silvio Danese  ^17    
1 Alimentive Inc / University of Western Ontario, London, Canada
² Université de Lorraine, CHRU-Nancy, Nancy, France
³ University of California San Diego School of Medicine, La Jolla, United States
⁴ University of Amsterdam, Amsterdam, Netherlands
⁵ Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
⁶ Cedars-Sinai Medical Center, Los Angeles, United States
⁷ Atlanta Gastroenterology Associates, Atlanta, United States
⁸ GI Alliance Research, Southlake, United States
⁹ University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany
¹⁰ Arena Pharmaceuticals, a wholly-owned subsidiary of Pfizer Inc, New York, San Diego, United States
¹¹ IBD Center, Swedish Medical Center, Seattle, United States
¹² Az Delta, Roeselare, Belgium
¹³ Icahn School of Medicine at Mount Sinai, New York, United States
¹⁴ Feinstein IBD Center, Mount Sinai, New York, United States
¹⁵ University Hospitals Leuven, Leuven, Belgium
¹⁶ Arena Pharmaceuticals Development GmbH, a wholly-owned subsidiary of Pfizer Inc, New York, Zug, Switzerland
¹⁷ IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy

Session
Investigator studies in IBD II (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)